# Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

> **NCT02802345** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 274 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo
- **DRUG:** Sildenafil

## Key facts

- **NCT ID:** NCT02802345
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-30
- **Primary completion:** 2017-12-19
- **Final completion:** 2018-04-13
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802345, "Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02802345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*